40,300 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Purchased by Private Advisor Group LLC

Private Advisor Group LLC acquired a new position in Applied Therapeutics, Inc. (NASDAQ:APLT) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 40,300 shares of the company’s stock, valued at approximately $35,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd bought a new position in Applied Therapeutics during the third quarter worth about $149,000. Intech Investment Management LLC bought a new position in Applied Therapeutics during the third quarter worth about $162,000. SG Americas Securities LLC boosted its holdings in Applied Therapeutics by 169.0% during the fourth quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock worth $35,000 after buying an additional 25,601 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in Applied Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 56,302 shares of the company’s stock worth $479,000 after buying an additional 31,724 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in Applied Therapeutics by 18.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 313,355 shares of the company’s stock worth $268,000 after buying an additional 47,983 shares during the last quarter. 98.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on APLT. UBS Group restated a “neutral” rating and set a $2.00 target price (down previously from $13.00) on shares of Applied Therapeutics in a report on Monday, December 2nd. Royal Bank of Canada cut their price objective on Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating on the stock in a report on Friday, December 20th. Robert W. Baird cut their price objective on Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating on the stock in a report on Friday, November 29th. William Blair cut Applied Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, December 23rd. Finally, Citigroup cut their price objective on Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 29th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.10.

Applied Therapeutics Stock Performance

NASDAQ APLT opened at $0.57 on Friday. The stock has a market capitalization of $66.60 million, a price-to-earnings ratio of -0.36 and a beta of 1.88. Applied Therapeutics, Inc. has a 52 week low of $0.43 and a 52 week high of $10.62. The stock’s 50 day moving average price is $0.63 and its two-hundred day moving average price is $4.39.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.